RBC Capital lowered the firm’s price target on Adverum Biotechnologies (ADVM) to $4 from $5 and keeps a Sector Perform rating on the shares after its Q1 results. The company’s first US-based wet AMD pivotal study is underway and is enrolling both treatment-experienced and treatment-naive patients, though the firm’s reduced price target reflects Adverum’s financial overhang as it remains on the sidelines pending further de-risking, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Adverum Biotechnologies reports Q1 EPS ($2.25), consensus ($1.97)
- Adverum Biotechnologies: Promising Gene Therapy Developments and Financial Stability Justify Buy Rating
- Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress
- Adverum Biotechnologies reports Q4 EPS ($1.96), consensus ($1.38)
- Adverum Biotechnologies sees cash runway into 2H25